Synergistic antitumor effects of immune cell-viral biotherapy
- PMID: 16556847
- DOI: 10.1126/science.1121411
Synergistic antitumor effects of immune cell-viral biotherapy
Abstract
Targeted biological therapies hold tremendous potential for treatment of cancer, yet their use has been limited by constraints on delivery and effective tumor targeting. We combined an immune effector cell population [cytokine-induced killer (CIK) cells] with an oncolytic viral therapy to achieve directed delivery to, and regression of, tumors in both immunodeficient and immunocompetent mouse models. Preinfection of CIK cells with modified vaccinia virus resulted in a prolonged eclipse phase with the virus remaining hidden until interaction with the tumor. Whole-body imaging revealed that the cells retained their ability to traffic to and to infiltrate the tumor effectively before releasing the virus. These results illustrate the potential of combining biotherapeutics for synergistic effects that more effectively treat cancer.
Similar articles
-
Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.Gene Ther. 2008 May;15(10):753-8. doi: 10.1038/gt.2008.42. Epub 2008 Mar 20. Gene Ther. 2008. PMID: 18356814 Review.
-
A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.Gene Ther. 2007 Apr;14(8):638-47. doi: 10.1038/sj.gt.3302914. Epub 2007 Feb 1. Gene Ther. 2007. PMID: 17268533
-
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice.Gene Ther. 2007 Jan;14(1):20-9. doi: 10.1038/sj.gt.3302840. Epub 2006 Aug 17. Gene Ther. 2007. PMID: 16915291
-
Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.Cancer Gene Ther. 2009 Apr;16(4):320-8. doi: 10.1038/cgt.2008.87. Epub 2008 Oct 24. Cancer Gene Ther. 2009. PMID: 18949014
-
Advances in oncolytic viral therapy.Curr Opin Investig Drugs. 2006 Jun;7(6):549-59. Curr Opin Investig Drugs. 2006. PMID: 16784026 Review.
Cited by
-
Emerging delivery strategy for oncolytic virotherapy.Mol Ther Oncol. 2024 Apr 29;32(2):200809. doi: 10.1016/j.omton.2024.200809. eCollection 2024 Jun 20. Mol Ther Oncol. 2024. PMID: 38845744 Free PMC article. Review.
-
Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer.Mol Ther Oncol. 2024 Feb 29;32(1):200788. doi: 10.1016/j.omton.2024.200788. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596310 Free PMC article. Review.
-
Oncolytic viruses: A novel treatment strategy for breast cancer.Genes Dis. 2021 Dec 16;10(2):430-446. doi: 10.1016/j.gendis.2021.11.011. eCollection 2023 Mar. Genes Dis. 2021. PMID: 37223527 Free PMC article. Review.
-
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.Front Immunol. 2022 Oct 13;13:1012806. doi: 10.3389/fimmu.2022.1012806. eCollection 2022. Front Immunol. 2022. PMID: 36311790 Free PMC article. Review.
-
Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer.Front Oncol. 2022 Aug 17;12:948405. doi: 10.3389/fonc.2022.948405. eCollection 2022. Front Oncol. 2022. PMID: 36059606 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
